Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objective: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing chemotherapy. Further, to assess whether quality-adjusted life-years (QALYs) can provide the basis for an appropriate measure of the value of supportive care interventions.
Design: A modelling study drawing cost and effectiveness assumptions from a literature review and from 3 US clinical trials involving more than 4500 patients with cancerwhowere treatedwith chemotherapy, radiotherapy, epoetin and blood transfusions as needed under standard care for patients with cancer.
Main outcome measures and results: When compared with transfusions, epoetin is cost effective under varying assumptions, whether effectiveness is measured by haemoglobin level or quality of life. Specifically, under a base-case scenario, the effectiveness resulting from $US1 spent on standard care can be achieved with only $US0.81 of epoetin care. Due in part to the health-state dependence of the significance patients attach to incremental changes in their responses on the linear analogue scale, cost per QALY results are ambiguous in this supportive care context.
Conclusions: Under a broad range of plausible assumptions, epoetin can be used cost effectively in the treatment of anaemic patients with cancer. Further, QALYs have limited applicability here because, as a short term supportive treatment, epoetin enhances the quality but not the length of life. Future research would benefit from the establishment of consistent values for quality-of-life changes across patients and health status, and the extension of the QALY framework to supportive care.
- Abels, R (1993) Erythropoietin for anemia in cancer patients. Eur J Cancer 29: pp. 2-8 CrossRef
- Case, D, Bukowski, R, Carey, R (1993) Recombinant-human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: pp. 801-6 CrossRef
- Glaspy, J, Bukowski, R, Steinberg, D (1997) The impact of therapy with epoetin alfa on clinical outcomes during cancer chemotherapy in community oncology practice. J Clin Oncol 15: pp. 1218-34
- Demetri, G, Kris, M, Wade, J (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16: pp. 3412-25
- Sheffield, R, Sullivan, S, Saltiel, E (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31: pp. 15-22
- Finkelstein, S, Huber, S, Greenberg, P (1997) Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31: pp. 1094
- Barosi, G, Marchetti, M, Liberato, NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78: pp. 781-7 CrossRef
- Ortega, A, Dranitsaris, G, Puodziunas, ALV (1998) What are cancer patients willing to pay for prophylactic epoetin alfa. Cancer 83: pp. 2588-96 CrossRef
- Gold, MR, Siegel, JE, Russell, LB (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press.
- Padilla, GV, Grant, MM, Ferrell, QL and cancer. In: Spilker, B eds. (1996) Quality-of-life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia (PA), pp. 301-8
- McCormack, H, Horne, D, Sheather, S (1988) Clinical applications of visual analogue scales: a critical review. Psychol Med 18: pp. 1007-19 CrossRef
- Shulman, K, Linas, B (1997) Pharmacoeconomics: state of the art in 1997. Annu Rev Public Health 18: pp. 529-48 CrossRef
- Yellen, S, Cella, D, Webster, K (1997) Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 13: pp. 63-74 CrossRef
- Cantor, S, Hudson, D, Lichtiger, B (1998) The costs of blood transfusion: a process flow analysis. J Clin Oncol 16: pp. 2364-70
- Mohandas, K, Aledort, L (1995) Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 35: pp. 427-30 CrossRef
- Part B extract summary system. Baltimore (MD): HCFA.
- American Cancer Society. Estimated new cancer cases [on line]. Available from: URL: http://www.cancer.org/statistics/cff98-/graphicaldata.html. [accessed 1999 Aug 11]
- Mehrez, A, Gafni, A (1993) Healthy-year equivalent versus quality-adjusted life years: in pursuit of progress. Med Decis Making 13: pp. 287-92 CrossRef
- Nord, E (1991) The validity of a visual analogue scale in determining social utility weights for health states. Int J Health Plann Manage 6: pp. 234-42 CrossRef
- Leplège, A, Hunt, S (1997) The problem of QL in medicine. JAMA 278: pp. 47-50 CrossRef
- Crown, WH, Obenchain, RL, Englehart, L (1998) The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Stat Med 17: pp. 1943-58 CrossRef
- Meltzer, D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16: pp. 33-64 CrossRef
- Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care
Volume 16, Issue 5 , pp 459-472
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Analysis Group/Economics, One Brattle Square, Cambridge, Massachusetts, 02138, USA
- 2. Department of Economics, University of Quebec, Montreal, Quebec, Canada
- 3. Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
- 4. Duke University Medical Center, Durham, North Carolina, USA
- 5. Clinical Affairs, Ortho Biotech Inc., Raritan, New Jersey, USA